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Abstract
Purpose To construct a model to predict preference-
adjusted EuroQol 5D (EQ-5D) health utilities for CS using
the disease-specific health-related quality of life measure
(CushingQOL).
Methods Data were obtained from the European Registry
on CS (ERCUSYN). ERCUSYN is a web-based, multi-
center, observational study that enrolled 508 CS patients
from 36 centers in 23 European countries. Patients included
in the study completed both the EQ-5D and the disease-
specific CushingQOL questionnaire. Socio-demographic
and clinical data were also collected. The UK tariff values
were used to calculate EQ-5D utility scores. Various pre-
dictive models were tested, and the final model was
selected based on four criteria: explanatory power (adjus-
ted R-squared), consistency of estimated coefficients (sign
and parameter estimation), normality of prediction errors
(mean error, mean absolute error, root mean squared error),
and parsimony.
Results For the mapping analysis, data were available
from a total of 129 patients. Mean (SD) age was 43.1 (13)
years, and the sample was predominantly female (84.5 %).
Patients had a mean (SD) CushingQOL score of 39.7 (17.1)
and a mean (SD) ‘tariff’ value on the EQ-5D of 0.55 (0.3).
The model which best met the criteria for selection inclu-
ded the intercept and 3 CushingQOL’s questions and had
an R2 of 0.506 and a root mean square error of 0.216.
Conclusions It was possible to find a mapping function
which successfully predicted the EQ-5D UK utilities from
disease-specific CushingQOL scores. The function may be
useful in calculating EQ-5D scores when EQ-5D data have
not been gathered directly in a study.
Keywords Cushing’s syndrome  Mapping 
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Introduction
Cushing’s syndrome (CS) is a rare hormonal disorder
caused by chronic exposure to hypercortisolism, with an
annual incidence of 2–3 cases per million [1]. It produces
many symptoms and disorders including central obesity,
gonadal dysfunction, hirsutism, delayed wound healing,
muscle weakness, hypertension, hyperglycemia, osteopo-
rosis, and depression, among others [2]. Psychiatric and
psychological disturbances associated with the active
hypercortisolemic state include mood disorders, particu-
larly major depression, but also mania, anxiety disorders,
psychological symptoms, and cognitive impairment, and it
has been found that quality of life may be seriously
impaired during both active and post-treatment phases [3].
Patients have also reported being particularly bothered by
fatigue/ weakness and changes in physical appearance, as
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well as interference with family life and relations with their
partner and impaired school or work performance [4].
Studies have shown that even patients who have been cured
of the disease score lower in terms of general well-being,
anxiety and depression, and overall quality of life than
healthy controls [5]. For all of these reasons, it has been
suggested that assessment of health-related quality of life
(HRQOL) in Cushing’s patients is of prime importance and
that it should complement existing clinical indicators of
health status [3, 6].
To date, several studies have evaluated HRQOL in
patients with CS, though the majority have used generic
HRQOL measures such as the SF-36 [7], the SF-12 [8] and/or
measures of specific symptoms associated with the disease,
such as the Hospital Anxiety and Depression Scale [9]. It
was only relative recently that a disease-specific measure
(the CushingQOL) became available to measure HRQOL in
patients with the condition [6, 10–12].
In addition to simply assessing HRQOL in patients with
CS, it can also be important to obtain social preferences
(or health utilities) for the disease states associated with the
disease. Health utilities are of particular importance in
economic evaluations of health-care technologies and
interventions. Instruments used to collect and provide
health utilities include the EuroQol 5D (EQ-5D) [13], the
SF-6D [14, 15], and the Health Utilities Index [16]. In
cases where this type of preference-based measure was not
included in the initial data collection, but a disease-specific
measure was, it may be possible to create a preference
function which allows scores on the disease-specific mea-
sure to be ‘mapped’ to index values on the preference-
based instrument. If mapping is successful, this approach
can allow cost-utility measurements to be carried out even
when a preference-based instrument was not used in the
initial evaluation of an intervention [17].
Currently, health utilities for the EQ-5D are not avail-
able for Cushing’s syndrome patients. The aim of the
present study was therefore to construct a prediction model
to obtain EQ-5D health utilities for CS using scores on a
disease-specific HRQOL measure (CushingQOL).
Methods
Study sample and data collection
Data used in the present analysis were from the European
Registry on CS (ERCUSYN) [12]. ERCUSYN is a web-
based, multicenter, observational study that enrolled CS
patients from 36 centers in 23 European countries diag-
nosed after January 1, 2000, to October 31, 2010. The
study used a mixture of prospective and retrospective
recruitment, though primarily prospective. Patients were
classified in the following four major groups depending on
the diagnosis: pituitary-dependent CS (PIT-CS), adrenal-
dependent CS (ADR-CS), CS from an ectopic source
(ECT-CS), and CS from other etiologies (OTH-CS). Etio-
logic classification was based on histologic documentation
of ACTH-secreting or adrenal tumor or biochemical and
clinical resolution of hypercortisolism after surgical
resection if histological reports were not available. Patients
with adrenal cancer were excluded from the database. For
the purposes of the mapping exercise, only the PIT-CS and
ADR-CS patients were used.
Data collected in the ERCUSYN database included
information on patients at diagnosis, such as baseline
demographic and anthropometric characteristics, etiology
of CS and diagnosis date, comorbidities, and bone status,
among others. HRQOL was measured using the Cushi-
ngQOL and the EQ-5D. Detailed data were also collected
on CS therapy, and the long-term outcomes of treatment
were assessed based on biochemistry and imaging param-
eters, post-treatment hormone replacement therapies,
pituitary deficiencies, clinical features, QOL, and bone
status. Urine 24-h free cortisol (UFC) levels were also
collected in each visit and were assessed by physicians to
determine whether they were within the range of normal
values.
The ERCUSYN study was approved by the ethics
committee of the Hospital Sant Pau, Barcelona, Spain,
which was the coordinating center for the project. Local
ethics committee for each participating institution also
approved the study, and all patients provided written or
verbal informed consent to participate, depending on
national legal requirements.
As mentioned, HRQOL in the ERCUSYN study was
measured using the CushingQOL [6] and the EQ-5D [13].
CushingQOL
The CushingQOL is a disease-specific questionnaire
designed to assess HRQOL in CS. It is a self-reported
instrument consisting of 12 questions which cover the areas
of trouble sleeping, wound healing/bruising, irritability/
mood swings/anger, self-confidence, physical changes,
ability to participate in activities, interactions with friends
and family, memory issues, and future health concerns.
Content for the questionnaire was derived from interviews
with 10 patients with the condition [10]. Patients respond
on Likert scales with five response categories (‘Always,’
‘Often,’ ‘Sometimes,’ ‘Rarely,’ and ‘Never,’ or ‘Very
much,’ ‘Quite a bit,’ ‘Somewhat,’ ‘Very little,’ and ‘Not at
all’). Responses are scored on a scale of 1–5, where ‘1’
corresponds to ‘Always’ or ‘Very much’ and ‘5’ to ‘Never’
or ‘Not at all.’ The overall score is calculated by summing
responses on all items and ranges from 12 (worst HRQOL)
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to 60 (best HRQOL). To facilitate the interpretation of
scores, they can be standardized on a scale from 0 (worst
HRQOL) to 100 (best HRQOL).
EQ-5D
The EQ-5D is a generic, preference-based instrument
which measures health status in 5 dimensions: mobility,
self-care, usual activities, pain and discomfort, and anxiety
and depression [18]. Each dimension has three response
levels: no problems, some problems and either extreme
problems (in the case of the pain/discomfort and anxiety/
depression dimensions), unable to (in the case of self-care
and usual activities) or confined to bed (in the case of
mobility). Utility indices for the EQ-5D are available for
several countries and provide weights on a scale anchored
at 0 (dead) to 1 (full health) for each of the 243 states
defined by the descriptive system. These are used for the
estimation of QALYs, based on the stated preferences of
members of the general public [19]. Respondents are also
asked to rate their overall health status on a 0–100 hash-
marked, vertical visual analog scale (EQ-VAS) on which 0
represents the worst imaginable health state and 100 rep-
resents the best possible imaginable health state. For the
present analysis, health utilities derived from the UK value
set were used [20], and derived using the following
formula:
Utility value
¼ 1  0:081 if at least one 2 or 3ð Þ
 0:269 if at least one 3ð Þ
 0:069 if mobility ¼ 2ð Þ  0:314 if mobility ¼ 3ð Þ
 0:104 if self care ¼ 2ð Þ  0:214 if self care ¼ 3ð Þ
 0:036 if usual activities ¼ 2ð Þ
 0:094 if usual activities ¼ 3ð Þ
 0:123 if pain/discomfort ¼ 2ð Þ
 0:386 if pain/discomfort ¼ 3ð Þ
 0:071 if anxiety/depression ¼ 2ð Þ
 0:236 if anxiety/depression ¼ 3ð Þ:
For full health (11111), a utility value of 1 is assigned.
Other variables
Socio-demographic data (age, gender, level of education,
employment status) and the following clinical variables
were collected: blood pressure, date of diagnosis of CS,
clinical type (pituitary or adrenal adenoma), UFC levels,
presence of symptoms (muscle weakness, loss of libido,
hair loss, menstrual irregularity, hirsutism, etc.), use of
pharmacological treatment, prior surgical intervention for
the disease, and comorbidities. UFC levels were reported
for each follow-up visit. As the normality of these values
was not assessed by a centralized laboratory, physicians
were asked to classify them as (1) ‘against diagnosis’ (i.e.,
normal values), or (2) ‘supporting diagnosis’ (high or
abnormal values).
Model development and selection
Regression analysis was used to analyze the relationship
between the EQ-5D utility score and scores on individual
items in the CushingQOL. In all models, the dependent
variable was the EQ-5D utility score. Models were additive
Generalized Linear Models incorporating main effects.
Several different models were tested to determine which
was the best, based on criteria described below. The
models included clinical and socio-demographic variables
as well as individual CushingQOL items and different
categorizations of CushingQOL scores as independent
variables, transformations (logarithm or square root) of
scores, interactions, and/or quadratic terms as predictors.
Tobit models were also tested using a value of ‘1’ (perfect
health on the EuroQol index) as the left-censored value.
Clinical and socio-demographic variables were initially
tested for potential inclusion in the models by determining
whether they showed a statistically significant association
with EQ-5D utility scores. Categorical variables were
analyzed using analysis of variance and continuous vari-
ables using Pearson’s correlation coefficient.
With regard to the CushingQOL itself, and the overall
score, each item was tested individually in the models, by
including them as discrete dummy variables (always vs.
other response options). Items included were those which
were significant at p \ 0.01 in bivariate analysis. We also
tested the following categorizations of CushingQOL scores
by including them as dummy variables: presence of ‘1’ in
any of the items answered; presence of ‘5’ in any of the
items answered; overall score B 20, between 21 and 40,
between 41 and 60, between 61 and 80, and [80.
Analyses were performed using SAS (PROC REG and
PROC GLM for ORL models). The following four criteria
were used to select the final model: the model’s explana-
tory power (assessed using adjusted R-squared); the con-
sistency of the estimated coefficients (sign and parameter
estimation); normality of prediction errors; and simplicity.
The normality of the prediction errors was assessed using
mean error (ME), mean absolute error (MAE), root mean
squared error (RMSE), and a percentage error under 5, 10,
and 15 % of the overall scale of independent variable. The
model’s simplicity was evaluated by determining whether
predictors were readily available and how many predictor
variables the model required. The criterion of simplicity
was important in order to optimize model usability. In
Qual Life Res (2013) 22:2941–2950 2943
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general in this type of modelling exercise, simple additive
models performed almost as well as more complex models
providing little extra advantage [17].
Results
A total sample of 511 patients with PIT-CS or ADR-CS
diagnosis was included in ERCUSYN registry. A final
sample of 129 evaluable patients (98 with PIT-CS and 31
with ADR-CS) was included in the analysis, and 382
patients were excluded because of missing data on either
the EQ-5D or the CushingQOL. Table 1 shows the basic
socio-demographic and clinical characteristics of the
mapping sample. Patients from 17 countries were included
(Austria, Belgium, Bulgaria, Czech Republic, England,
Estonia, France, Germany, Hungary, Italy, Latvia, The
Netherlands, Norway, Portugal, Spain, Sweden, and Tur-
key). France included the highest number of patients
(n = 35) and England, Germany, and Norway the fewest
(n = 1).
Table 2 shows the score distributions on the Cushi-
ngQOL and EQ-5D. The mean (SD) score on the Cushi-
ngQOL was 39.7 (17.1). The EQ-5D showed a mean (SD)
index score of 0.55 (0.3) on a scale of -0.59 to 1, and
minimum and maximum scores of -0.32 and 1.
Figure 1 shows the relative distribution of CushingQOL
and EQ-5D total scores in the basic, two variable regres-
sion models. While it can be seen that the CushingQOL
scores follow a relatively normal distribution, this is not
true for EQ-5D index scores, which are skewed substan-
tially to the right, that is, toward better HRQOL.
Figure 2 shows the results of regressing the EQ-5D
overall scores on CushingQOL overall scores. Higher EQ-
5D index scores correspond to higher CushingQOL scores,
though approximately 15 % of the CushingQOL scores
recorded corresponded to EQ-5D values at or under 0.1,
which represent extremely poor health states; 9.3 % had
utility scores under 0, representing health states worse than
death. Based on the slope, a 10 unit increase in the
CushingQOL would be equivalent to an increase of almost
0.1 on the utility scale. The correlation between the two
scores was 0.604.
Table 3 shows the results of testing the most promising
models. In bivariate analyses, variables showing a statis-
tically significant (p \ 0.05) correlation with EQ-5D utility
values were questions 2, 4, 5, and 10, and these can be
considered to constitute the final model which we recom-
mend for utility prediction with EQ-5D. Although having a
diagnosis of clinical depression and employment status was
also significant in the model, they were not included in
order to simplify the model and because the relevance of
employment status within the model was not clear. None of
the other socio-demographic and clinical variables tested
showed a statistically significant relationship with EQ-5D
utility scores. The model which best met the criteria of
explanatory power, consistency of estimated coefficients,
normality of prediction errors, and simplicity was therefore
Model 1. This model incorporated only 3 dummy variables,
which take into account the impact of CushingQOL ques-
tions 2, 5, and 10. Although Models 2 and 4 showed a
slightly better adjusted R2 than Model 1, the difference
was minimal and came at the expense of less simple
models. Utility values derived from model 1 can be
obtained applying the following formula:
Table 1 Socio-demographic and clinical characteristics of the ori-
ginal validation study sample in ERCUSYN database
Characteristic N = 129
Mean (SD) age in years 43.3 (13.1)
Sex, female, n (%) 109 (84.5 %)
Education, secondary or university studies, n (%) 92 (71.3 %)
Time since diagnosis in months, mean (SD) 7.0 (9.8)
Clinical type, n (%)
Adrenal adenoma 31 (24.0 %)
Pituitary dependent 98 (76.0 %)
UFC (nmol/24 h), mean (SD) 1023.4 (1051.7)
UFC interpretation, n (%)
Supporting diagnosis 107 (83.0 %)
Against diagnosis 8 (6.2 %)
Not available 14 (10.8 %)
Receiving pharmacological treatment for CS,
n (%)
28 (22 %)
Prior surgery, n (%) 77 (59.7 %)
Concomitant morbidities, n (%)
Weight gain 107 (83 %)
Hypertension 94 (72.9 %)
Cushing’s skin symptoms 102 (79.1 %)
Diagnosed fractures 24 (18.6 %)
Depression 46 (35.7 %)
Diabetes mellitus 35 (27.1 %)
Muscle weakness 91 (70.5 %)
Loss of libido 31 (24.0 %)
Hair loss 34 (26.4 %)
Hirsutism 54 (41.9 %)
Irregular periods 57 (44.2 %)
CushingQOL score
Mean (SD) 39.7 (17.1)
Median (IQR) 39.6 (25)
EQ-5D utility values
Mean (SD) 0.55 (0.30)
Median (IQR) 0.62 (0.21)
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Utility value ¼0:835  0:485 if level 1 in Q-02ð Þ
 0:214 if level 2 in Q-02ð Þ
 0:154 if level 3 in Q-02ð Þ
 0:139 if level 1 or 2 in Q-05ð Þ
 0:219 if level 1 in Q-10ð Þ:
Table 4 shows the results of analyzing the residuals in
the selected models. Differences between observed and
estimated mean and median values were generally small in
all models. Error terms were obviously larger for maximum
and minimum values because of much smaller number of
patients scoring at the extremes. Although none of the
prediction errors showed a normal distribution (Kolmogo-
rov–Smirnov and Shapiro–Wilks p = 0.02), visual
inspection showed their distribution to be reasonably close
to normal.
Figure 3 provides a graphic representation of predicted
values and residuals using the final model. Higher values
on the EQ-5D values are reflected in higher EQ-5D pre-
dicted values.
Discussion
The EQ-5D is one of the most widely used measures of
health status which also provides utility values for use in
cost-effectiveness analyses. Having a mapping algorithm
available to transform CushingQOL scores to EQ-5D
utility values may therefore be very useful when it is not
possible to obtain EQ-5D data directly from patients. In the
present study, we derived a simple predictive model to map
scores from the CushingQOL to the EQ-5D using data from
the ERCUSYN study. The final model selected met our
criteria for simplicity, consistency, and explanatory power,
and prediction errors which did not deviate substantially
from a normal distribution.
The final model selected included only 3 predictor
variables, those being questions 2, 5, and 10 of the
CushingQOL, though for the latter two questions only
response levels 1 and 2 (representing the highest levels of
severity) proved to be relevant for the model. These
questions relate, respectively, to having pain that keeps the
patient from leading a normal life, being more irritable or
Table 2 Score distributions on the CushingQOL and EQ-5D
Values Mean Theoretical range Standard deviation Minimum Median Maximum Valid N
CushingQOL 39.71 0–100 17.05 0 39.58 83.33 129
EQ-5D utilities 0.550 -0.594 to 1 0.300 -0.319 0.620 1 129
Fig. 1 Distributions of CushingQOL scores and EQ-5D utility values
in the simplest, reference model
Fig. 2 Correlation between CushingQOL scores and EQ-5D utility
values in the reference model
Qual Life Res (2013) 22:2941–2950 2945
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having sudden mood swings and angry outbursts, and the
illness affecting everyday activities such as working or
studying. These aspects of the CushingQOL clearly relate
to individual dimensions on the EQ-5D which may explain
why they were found to be the most relevant for the pre-
dictive model. Other questions in the CushingQOL may not
have such a strong affinity with EQ-5D dimensions, which
means they were not included in the model. However,
despite the fact that conceptual overlap between the two
instruments may not be high, the final model selected
explained approximately 50 % of the variance in EQ-5D
scores with a mean absolute error of 0.16. These results are
similar to those observed in other studies which have mapped
scores between different HRQOL instruments, including the
EQ-5D [21–25]. Although other authors have questioned
whether modeling should take place when there is a manifest
lack of conceptual overlap between instruments [26], we
consider the results of the present mapping exercise to be
acceptable in terms of model performance parameters. It
may be optimistic to expect greatly higher predictive
capacity when mapping from disease specific to generic
instruments. Likewise, although the model performs rea-
sonably well on accepted performance parameters, it can
clearly lead to predictive errors at the individual level that
could be very high. For that reason, the model should only
be used at the aggregate level, and not to estimate utilities
for individual patients. Finally, it should be pointed out that
modeling of this type is always a second-best choice to
obtaining utilities by administering EQ-5D or other pref-
erence-based instruments directly in the population of
interest.
A range of additional variables, as well as interaction
terms, was tested to see whether they should be included in
the models. However, only depression and employment
Table 3 Comparison of results obtained with the most promising models and the reference model (Model 1)
Parameter Model 1 Model 2 Model 3 Model 4
N obs used 128 128 126 128
Intercept 0.835 0.844 -1.392 0.245
Level 1 in Q-02 -0.485 -0.470 0.920 0.360
Level 2 in Q-02 -0.214 -0.207 0.514 0.185
Level 3 in Q-02 -0.154 -0.140 0.384 0.170
Level 4 in Q-02 -0.086 (ns) -0.092 (ns) 0.064 (ns) 0.097
Level 1 in Q-04 0.111 (ns)
Level 2 in Q-04 0.200
Level 3 in Q-04 0.181
Level 4 in Q-04 0.034 (ns)
Level 1 in Q-05 20.139 -0.183 0.321
Level 2 in Q-05 20.139 -0.110 (ns)
Level 3 in Q-05 -0.011 (ns)
Level 4 in Q-05 0.073 (ns)
Presence of ‘‘1’’ or ‘‘2’’ in Q-05 0.116
Level 1 in Q-10 20.219 -0.246 0.306 0.157
Level 2 in Q-10 -0.046 (ns)
Level 3 in Q-10 -0.033 (ns)
Level 4 in Q-10 -0.048 (ns)
Model fit statistics
R2 0.5060 0.5196 0.4285* 0.5619*
Adj R2 0.4815 0.4695 0.3992* 0.5244*
RMSE 0.2163 0.2188 0.4423* 0.1552*
0.2280 0.2025
MAE 0.160 0.158 0.161 0.153
Responses Level 1 (always), level 2 (often), level 3 (sometimes), and level 4 (rarely). Level 5 (never) is reference category
Values indicated in bold denote that the model 1 was chosen as the better one
MAE, mean absolute error; RMSE, root mean square error; Q-02, I have pain that keeps me from leading a normal life; Q-04, I bruise easily;
Q-05, I am more irritable, I have sudden mood swings and angry outbursts; Q-10, My illness affects my everyday activities such as working or
studying; Model 1 and model 2, ORL using utility values (UV) without transformations; Model 3, ORL using as response log((-1 9 UV) ? 1);
Model 4, ORL using as response sqrt((-1 9 UV) ? 1)
* Values obtained directly from the model, prior to un-transforming to original utility values
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status showed a statistically significant relationship with
utilities and their inclusion in the models would help to
improve the model’s adjustment. Nevertheless, it was
decided not to include them in the models because data on
the presence of clinical depression might not always be
readily available and so would complicate application of
the model, and because the conceptual relationship
between employment status and utility values was insuffi-
ciently convincing to be included.
Alternative approaches to modeling were tested, such as
using a Tobit model to take into account the skewed dis-
tribution on the EQ-5D, but found that it did not offer any
advantages over the GLM models. In terms of usability,
this is a relatively simple model, so it should not be too
difficult to apply. However, users should be aware that the
model is only relevant for the MVH UK tariff. Researchers
wishing to transfer CushingQOL scores to other EQ
country-specific tariffs would need to determine whether
Table 4 Analysis of residuals in the most promising models
Observed EQ-5D score Predicted EQ-5D score Error term Absolute error term Square error
Model 1
Mean 0.548 0.548 0 0.160 0.044
SD 0.300 0.214 0.211 0.137 0.070
Minimum -0.319 -0.008 -0.599 0.001 0.000
Q1 0.516 0.462 -0.129 0.044 0.002
Median 0.620 0.610 0.030 0.138 0.019
Q3 0.725 0.696 0.147 0.223 0.050
Maximum 1.000 0.835 0.628 0.628 0.395
N 128a 128 128 128 128
Model 2
Mean 0.548 0.548 0 0.158 0.043
SD 0.300 0.217 0.208 0.135 0.071
Minimum -0.319 -0.055 -0.566 0.001 0.000
Q1 0.516 0.448 -0.124 0.052 0.003
Median 0.620 0.581 0.030 0.131 0.017
Q3 0.725 0.705 0.131 0.212 0.045
Maximum 1.000 0.917 0.675 0.675 0.456
N 128 128 128 128 128
Model 3
Mean 0.551 0.583 0.032 0.161 0.052
SD 0.300 0.186 0.226 0.161 0.098
Minimum -0.319 -0.143 -0.763 0.004 0.000
Q1 0.516 0.511 -0.098 0.049 0.002
Median 0.620 0.637 -0.014 0.098 0.010
Q3 0.725 0.738 0.118 0.250 0.062
Maximum 1.000 0.750 0.659 0.763 0.582
N 126b 126 126 126 126
Model 4
Mean 0.548 0.570 0.022 0.153 0.041
SD 0.300 0.223 0.202 0.134 0.067
Minimum -0.319 0.021 -0.599 0.001 0.000
Q1 0.516 0.447 -0.078 0.052 0.003
Median 0.62 0.627 -0.002 0.104 0.011
Q3 0.725 0.726 0.136 0.233 0.054
Maximum 1.000 0.940 0.584 0.599 0.359
N 128 128 128 128 128
Log(-1 ? 1) = log(0) = NA
a 128 observations used in this analysis because of a missing value in question 10
b Only 126 observations used in this model as the log transformation of 1 is not a valid operation
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the same model can be applied, or whether they prefer to
use the MVH UK tariff in other countries. It is also
important to note the effects of the model when estimating
values, such as the tendency to underestimate EQ-5D
utilities across the measurement spectrum or to provide less
reliable estimates at the extremes of the utility scale,
especially in patients scoring below 0.2. If the utility values
are to be used in economic modeling, these effects of the
model could be taken into account to some extent in sen-
sitivity analysis, by providing a range of possible EQ-5D
utilities for specific categories of CushingQOL scores.
The ERCUSYN study represents the largest collabora-
tion of endocrine centers in Europe and in the world in
patients with CS [12]. Its strong points include the large
sample size and the use of a standardized data collection
protocol across all countries and centers. It is also the most
recent large-scale study performed in CS patients, so the
data should provide a very up-to-date picture of the impact
of the disease and its treatment on health status and QOL.
However, it was not the intention of the ERCUSYN reg-
istry to achieve a representative sample of CS patients in
Europe. Clearly, this would have been preferable for
mapping purposes. A noteworthy finding of the ERCUSYN
study was the low EQ-5D index score (0.55). This was
similar to or lower than index scores observed in patients
with chronic heart failure [27] or COPD [28] and only a
little higher than scores in patients with clinical depression
[29]. Also of note was the fact that approximately 15 % of
the subjects rated their own health on the EQ-5D as equal
to or lower than 0.1, which represent a very low score
indeed, and some of the patients even had ratings which
would be equivalent to health states worse than death. This
indicates the substantial impact of CS, though it should be
noted that the scores on the CushingQOL observed here
were considerably lower than the mean (SD) score of 53
(22) observed in the original validation study of the
instrument [6], suggesting that the patients in the ERUS-
CYN study had considerably worse disease-specific health
status than those in the earlier study. In fact, in the original
validation study, 85 % had undergone surgery (more than
the 59.7 % reported here) and only 31 % were hypercor-
tisolemic compared to 83 % reported here. Finally,
although a total of 511 patients were included for the final
analysis in the ERCUSYN study itself, for the mapping
exercise, only data from 129 patients could be used.
Quality of life data were not collected from all patients
because the study was carried out in conditions of usual
clinical practice, and it was not always feasible for inves-
tigators to administer both of the HRQOL questionnaires.
Study limitations
The fact that so many patients had to be excluded from the
mapping analysis due to missing data on the EQ-5D and/or
the CushingQOL questionnaire is an obvious limitation of
the present exercise, as it lowered the sample size available
and also threatened the sample makeup. Although the
ERCUSYN study did not aim to provide a representative
sample of CS patients, the reduction from 481 to 129
patients clearly leads to concerns about whether the
patients used in the present exercise were even represen-
tative of the ERCUSYN sample or whether they could have
represented an anomalous group. For that reason, we
compared characteristics between the sub-group and the
full ERCUSYN population to determine the extent to
which the sub-group used in the present analysis was
representative of the full ERCUSYN sample. Statistically
significant differences were not found between groups on
any of the major socio-demographic and clinical variables
except employment status, in which there were propor-
tionally fewer retired subjects in the sub-group analyzed
here.
The limited sample size did not allow to test whether the
model worked equally well in sub-samples of the overall
population, for example, in PIT-CS and ADR-CS, or across
different countries. Sample size calculations indicated that
for six independent variables in the final model, we would
require a minimum of 126 patients [30]. It would be
interesting to evaluate this further in future studies, though
as CS is a rare disease, it will usually be difficult to achieve
sufficiently large samples. Regarding the issue of countries,
as we only used the UK tariff of social values to obtain
EQ-5D index scores, these values may not reflect the val-
ues of subjects in other countries. For example, some dif-
ferences were found between the UK and Spain in terms of
the weights assigned to different EQ-5D dimensions [31].
However, given the large number of countries involved and
Fig. 3 Predicted values and residuals using the final model
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the relatively small number of patients in each country,
using different country tariffs would not be practical and
would likely have a negligible effect on results. Likewise,
no country-specific tariff is available for many of the par-
ticipating countries. In these situations, it is often recom-
mended to apply the UK MVH tariff [19]. It should also be
remembered that the model may had differed if, say, only
patients from Spain or the UK had been included, as the
relationship between CushingQOL and EQ-5D scores
could have been affected. For example, if patients in the
UK were, for cultural reasons, less willing to report anxiety
and/or depression on the EQ-5D than their European
counterparts, this would presumably lead to different
coefficients for items related to that concept in the Cushi-
ngQoL, particularly if they were less willing to report
problems related to the concept on the CushingQOL as
well. However, this is only speculation, as there was
insufficient sample size to test this. Nevertheless, potential
users of the model should be aware of. A final limitation
was that a cross-validation test in another sample or in half
of the original sample was not performed as the sample size
was considered insufficient. It has been noted, though, that
testing models in other samples do not often lead to any
reduction in model performance [17].
In conclusion, the model developed here should be
useful in transferring CushingQOL scores to the EQ-5D
when the EQ-5D was not administered in the original study
and when researchers are interested in using the UK tariff.
The model should be easy to apply and showed acceptable
goodness of fit. Future studies could examine whether the
same model can be used with other country-specific utility
tariffs for the EQ-5D.
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